Calidi Biotherapeutics, Inc.
CLDI
$1.56
-$0.18-10.35%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.99% | -32.99% | -19.31% | -1.18% | 9.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.43% | -33.78% | -24.89% | -1.75% | 14.04% |
| Operating Income | 32.43% | 33.78% | 24.89% | 1.75% | -14.04% |
| Income Before Tax | 13.75% | 33.14% | 23.99% | 8.51% | 27.58% |
| Income Tax Expenses | -55.00% | -18.75% | -12.50% | -50.00% | 233.33% |
| Earnings from Continuing Operations | 13.79% | 33.13% | 23.98% | 8.53% | 27.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.60% | 33.61% | 24.21% | 8.59% | 27.53% |
| EBIT | 32.43% | 33.78% | 24.89% | 1.75% | -14.04% |
| EBITDA | 33.71% | 36.03% | 27.19% | 3.80% | -12.00% |
| EPS Basic | 72.58% | 90.66% | 85.39% | 82.10% | 82.37% |
| Normalized Basic EPS | 72.61% | 88.94% | 83.96% | 83.48% | 83.62% |
| EPS Diluted | 72.58% | 90.66% | 85.39% | 82.10% | 82.37% |
| Normalized Diluted EPS | 72.61% | 88.94% | 83.96% | 83.48% | 83.62% |
| Average Basic Shares Outstanding | 321.32% | 488.99% | 374.84% | 402.89% | 301.39% |
| Average Diluted Shares Outstanding | 321.32% | 488.99% | 374.84% | 402.89% | 301.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |